Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma

Jens Bedke; Laurence Albiges; Umberto Capitanio; Rachel H. Giles; Milan Hora; Thomas B. Lam; Börje Ljungberg; Lorenzo Marconi; Tobias Klatte; Alessandro Volpe; Yasmin Abu-Ghanem; Saeed Dabestani; Sergio Fernández-Pello; Fabian Hofmann; Teele Kuusk; Rana Tahbaz; Thomas Powles; Axel Bex

doi:10.1016/j.eururo.2020.12.005

Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma

Jens Bedke, Laurence Albiges, Umberto Capitanio, Rachel H. Giles, Milan Hora, Thomas B. Lam, Börje Ljungberg, Lorenzo Marconi, Tobias Klatte, Alessandro Volpe, Yasmin Abu-Ghanem, Saeed Dabestani, Sergio Fernández-Pello, Fabian Hofmann, Teele Kuusk, Rana Tahbaz, Thomas Powles, Axel Bex

Urological cancer, Malmö

Research output: Contribution to journal › Article › peer-review

Abstract

Longer follow-up and new trial data from phase 3 randomised controlled trials investigating immune checkpoint blockade (PD-1 or its ligand PD-L1) in advanced clear-cell renal cell carcinoma (RCC) have recently become available. The CheckMate 9ER trial demonstrated an improved progression-free survival (PFS) and overall survival (OS) benefit for the combination of cabozantinib plus nivolumab. A Keynote-426 update demonstrated an ongoing OS benefit for pembrolizumab plus axitinib in the intention-to-treat population, with a PFS benefit seen across all International Metastatic Database Consortium (IMDC) subgroups, while an update of CheckMate 214 confirmed the long-term benefit of ipilimumab plus nivolumab in IMDC intermediate and poor risk patients. The RCC Guidelines Panel continues to recommend these tyrosine kinase inhibitors + immunotherapy (IO) combination across IMDC risk groups in advanced first-line RCC and dual immunotherapy of ipilimumab and nivolumab in IMDC intermediate and poor risk. Patient summary: New data from trials of immune checkpoint inhibitors for advanced kidney cancer confirm a survival benefit with the combination of cabozantinib plus nivolumab and pembrolizumab plus axitinib and ipilimumab plus nivolumab. These combination therapies are recommended as first-line treatment for advanced kidney cancer.

Original language	English
Pages (from-to)	339-342
Number of pages	4
Journal	European Urology
Volume	79
Issue number	3
DOIs	https://doi.org/10.1016/j.eururo.2020.12.005
Publication status	Published - 2021 Mar

Subject classification (UKÄ)

Cancer and Oncology

Free keywords

Cabozantinib
Clear cell
First line
Nivolumab
Renal cell carcinoma
Systemic therapy
Treatment-naïve

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.eururo.2020.12.005

Fingerprint

Dive into the research topics of 'Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma'. Together they form a unique fingerprint.

Cite this

Bedke, J., Albiges, L., Capitanio, U., Giles, R. H., Hora, M., Lam, T. B., Ljungberg, B., Marconi, L., Klatte, T., Volpe, A., Abu-Ghanem, Y., Dabestani, S., Fernández-Pello, S., Hofmann, F., Kuusk, T., Tahbaz, R., Powles, T., & Bex, A. (2021). Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma. European Urology, 79(3), 339-342. https://doi.org/10.1016/j.eururo.2020.12.005

@article{cc847aa3bf644ce1872e008b8e244c37,

title = "Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-na{\"i}ve Metastatic Clear-Cell Renal Cell Carcinoma",

abstract = "Longer follow-up and new trial data from phase 3 randomised controlled trials investigating immune checkpoint blockade (PD-1 or its ligand PD-L1) in advanced clear-cell renal cell carcinoma (RCC) have recently become available. The CheckMate 9ER trial demonstrated an improved progression-free survival (PFS) and overall survival (OS) benefit for the combination of cabozantinib plus nivolumab. A Keynote-426 update demonstrated an ongoing OS benefit for pembrolizumab plus axitinib in the intention-to-treat population, with a PFS benefit seen across all International Metastatic Database Consortium (IMDC) subgroups, while an update of CheckMate 214 confirmed the long-term benefit of ipilimumab plus nivolumab in IMDC intermediate and poor risk patients. The RCC Guidelines Panel continues to recommend these tyrosine kinase inhibitors + immunotherapy (IO) combination across IMDC risk groups in advanced first-line RCC and dual immunotherapy of ipilimumab and nivolumab in IMDC intermediate and poor risk. Patient summary: New data from trials of immune checkpoint inhibitors for advanced kidney cancer confirm a survival benefit with the combination of cabozantinib plus nivolumab and pembrolizumab plus axitinib and ipilimumab plus nivolumab. These combination therapies are recommended as first-line treatment for advanced kidney cancer.",

keywords = "Cabozantinib, Clear cell, First line, Nivolumab, Renal cell carcinoma, Systemic therapy, Treatment-na{\"i}ve",

author = "Jens Bedke and Laurence Albiges and Umberto Capitanio and Giles, {Rachel H.} and Milan Hora and Lam, {Thomas B.} and B{\"o}rje Ljungberg and Lorenzo Marconi and Tobias Klatte and Alessandro Volpe and Yasmin Abu-Ghanem and Saeed Dabestani and Sergio Fern{\'a}ndez-Pello and Fabian Hofmann and Teele Kuusk and Rana Tahbaz and Thomas Powles and Axel Bex",

year = "2021",

month = mar,

doi = "10.1016/j.eururo.2020.12.005",

language = "English",

volume = "79",

pages = "339--342",

journal = "European Urology",

issn = "0302-2838",

publisher = "Elsevier",

number = "3",

}

Bedke, J, Albiges, L, Capitanio, U, Giles, RH, Hora, M, Lam, TB, Ljungberg, B, Marconi, L, Klatte, T, Volpe, A, Abu-Ghanem, Y, Dabestani, S, Fernández-Pello, S, Hofmann, F, Kuusk, T, Tahbaz, R, Powles, T & Bex, A 2021, 'Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma', European Urology, vol. 79, no. 3, pp. 339-342. https://doi.org/10.1016/j.eururo.2020.12.005

Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma. / Bedke, Jens; Albiges, Laurence; Capitanio, Umberto et al.
In: European Urology, Vol. 79, No. 3, 03.2021, p. 339-342.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Updated European Association of Urology Guidelines on Renal Cell Carcinoma

T2 - Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naïve Metastatic Clear-Cell Renal Cell Carcinoma

AU - Bedke, Jens

AU - Albiges, Laurence

AU - Capitanio, Umberto

AU - Giles, Rachel H.

AU - Hora, Milan

AU - Lam, Thomas B.

AU - Ljungberg, Börje

AU - Marconi, Lorenzo

AU - Klatte, Tobias

AU - Volpe, Alessandro

AU - Abu-Ghanem, Yasmin

AU - Dabestani, Saeed

AU - Fernández-Pello, Sergio

AU - Hofmann, Fabian

AU - Kuusk, Teele

AU - Tahbaz, Rana

AU - Powles, Thomas

AU - Bex, Axel

PY - 2021/3

Y1 - 2021/3

N2 - Longer follow-up and new trial data from phase 3 randomised controlled trials investigating immune checkpoint blockade (PD-1 or its ligand PD-L1) in advanced clear-cell renal cell carcinoma (RCC) have recently become available. The CheckMate 9ER trial demonstrated an improved progression-free survival (PFS) and overall survival (OS) benefit for the combination of cabozantinib plus nivolumab. A Keynote-426 update demonstrated an ongoing OS benefit for pembrolizumab plus axitinib in the intention-to-treat population, with a PFS benefit seen across all International Metastatic Database Consortium (IMDC) subgroups, while an update of CheckMate 214 confirmed the long-term benefit of ipilimumab plus nivolumab in IMDC intermediate and poor risk patients. The RCC Guidelines Panel continues to recommend these tyrosine kinase inhibitors + immunotherapy (IO) combination across IMDC risk groups in advanced first-line RCC and dual immunotherapy of ipilimumab and nivolumab in IMDC intermediate and poor risk. Patient summary: New data from trials of immune checkpoint inhibitors for advanced kidney cancer confirm a survival benefit with the combination of cabozantinib plus nivolumab and pembrolizumab plus axitinib and ipilimumab plus nivolumab. These combination therapies are recommended as first-line treatment for advanced kidney cancer.

AB - Longer follow-up and new trial data from phase 3 randomised controlled trials investigating immune checkpoint blockade (PD-1 or its ligand PD-L1) in advanced clear-cell renal cell carcinoma (RCC) have recently become available. The CheckMate 9ER trial demonstrated an improved progression-free survival (PFS) and overall survival (OS) benefit for the combination of cabozantinib plus nivolumab. A Keynote-426 update demonstrated an ongoing OS benefit for pembrolizumab plus axitinib in the intention-to-treat population, with a PFS benefit seen across all International Metastatic Database Consortium (IMDC) subgroups, while an update of CheckMate 214 confirmed the long-term benefit of ipilimumab plus nivolumab in IMDC intermediate and poor risk patients. The RCC Guidelines Panel continues to recommend these tyrosine kinase inhibitors + immunotherapy (IO) combination across IMDC risk groups in advanced first-line RCC and dual immunotherapy of ipilimumab and nivolumab in IMDC intermediate and poor risk. Patient summary: New data from trials of immune checkpoint inhibitors for advanced kidney cancer confirm a survival benefit with the combination of cabozantinib plus nivolumab and pembrolizumab plus axitinib and ipilimumab plus nivolumab. These combination therapies are recommended as first-line treatment for advanced kidney cancer.

KW - Cabozantinib

KW - Clear cell

KW - First line

KW - Nivolumab

KW - Renal cell carcinoma

KW - Systemic therapy

KW - Treatment-naïve

U2 - 10.1016/j.eururo.2020.12.005

DO - 10.1016/j.eururo.2020.12.005

M3 - Article

C2 - 33357997

AN - SCOPUS:85099364654

SN - 0302-2838

VL - 79

SP - 339

EP - 342

JO - European Urology

JF - European Urology

IS - 3

ER -